ArticleEMBO molecular medicine2014
R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice.
Article in EMBO molecular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 50 citations in OpenAlex.
- Antioxidant Therapies in the Treatment of Multiple Sclerosis.Biomolecules · 2024Review
- Article
- wSDTNBI: a novel network-based inference method for virtual screening.Chemical science · 2022Article
- Increased Fat Taste Preference in Progranulin-Deficient Mice.Nutrients · 2021Article
- Sapropterin (BH4) Aggravates Autoimmune Encephalomyelitis in Mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Observational
- Microglial Nox2 Plays a Key Role in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.Frontiers in immunology · 2021Article
- Intra-articular delivery of flurbiprofen sustained release thermogel: improved therapeutic outcome of collagenase II-induced rat knee osteoarthritis.Drug delivery · 2020Article
- Low brain endocannabinoids associated with persistent non-goal directed nighttime hyperactivity after traumatic brain injury in mice.Scientific reports · 2020Article
- Aberrant DNA methylation profile exacerbates inflammation and neurodegeneration in multiple sclerosis patients.Journal of neuroinflammation · 2020Review
- Target identification among known drugs by deep learning from heterogeneous networks.Chemical science · 2020Article
- Dual Actions of Ketorolac in Metastatic Ovarian Cancer.Cancers · 2019Review
- Dimethyl fumarate mitigates optic neuritis.Molecular vision · 2019Article
- Machine-learning based lipid mediator serum concentration patterns allow identification of multiple sclerosis patients with high accuracy.Scientific reports · 2018Article
- Article
- Therapeutic Effect of the Substrate-Selective COX-2 Inhibitor IMMA in the Animal Model of Chronic Constriction Injury.Frontiers in pharmacology · 2018Article
- Article
- Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis.Journal of neuroinflammation · 2017Article
- Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis.Acta neuropathologica communications · 2017Observational
- Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice.Journal of visualized experiments : JoVE · 2017Article
- Progress does not just come in giant leaps: adapting techniques for the study of inflammation to novel applications.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
R-flurbiprofen is the non-cyclooxygenase inhibiting R-enantiomer of the non-steroidal anti-inflammatory drug flurbiprofen, which was assessed as a remedy for Alzheimer's disease. Because of its anti-inflammatory, endocannabinoid-modulating and antioxidative properties, combined with low toxicity, the present study assessed R-flurbiprofen in experimental autoimmune encephalomyelitis (EAE) models of multiple sclerosis in mice. Oral R-flurbiprofen prevented and attenuated primary progressive EAE in C57BL6/J mice and relapsing-remitting EAE in SJL mice, even if the treatment was initiated on or after the first flare of the disease. R-flurbiprofen reduced immune cell infiltration and microglia activation and inflammation in the spinal cord, brain and optic nerve and attenuated myelin destruction and EAE-evoked hyperalgesia. R-flurbiprofen treatment increased CD4(+)CD25(+)FoxP3(+) regulatory T cells, CTLA4(+) inhibitory T cells and interleukin-10, whereas the EAE-evoked upregulation of pro-inflammatory genes in the spinal cord was strongly reduced. The effects were associated with an increase of plasma and cortical endocannabinoids but decreased spinal prostaglandins, the latter likely due to R to S inversion. The promising results suggest potential efficacy of R-flurbiprofen in human MS, and its low toxicity may justify a clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.